Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia
Authors:
- 1 August 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 30 (4) , 263-272
Abstract
Purpose of review: Non-HDL cholesterol was originally conceived as a therapeutic target for statin treatment in hypertriglyceridaemia when apolipoprotein B100 assays were not widely available. Recently non-HDL cholesterol has been recommended to replace LDL cholesterol in the clinical management of dyslipidaemia routinely in general medical practice. This is misguided. Recent findings: Non-HDL cholesterol is heterogeneous, constituting a mixture of triglyceride-rich VLDL, intermediate density lipoprotein and LDL in which small dense LDL is poorly represented and to which VLDL cholesterol contributes increasingly as triglyceride levels rise. This makes it unsuitable as a goal of lipid-lowering treatment or as an arbiter of who should receive such treatment. Results of trials designed to lower LDL cholesterol are not easily translated to non-HDL cholesterol. Fasting is no longer thought essential for screening the general population for raised LDL cholesterol. ApoB100 measurement also does not require fasting even in rarer more extreme lipoprotein disorders encountered in the Lipid Clinic, provides greater precision and specificity and overcomes the problems posed by LDL and non-HDL cholesterol. It is more easily interpreted both in diagnosis and as a therapeutic goal and it includes SD-LDL. Summary: If we are to discourage use of LDL cholesterol, it should be in favour of apoB100 not non-HDL cholesterol.Keywords
This publication has 38 references indexed in Scilit:
- Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetesDiabetes & Vascular Disease Research, 2010
- Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutationJournal of Clinical Lipidology, 2010
- Using Apolipoprotein B to Manage Dyslipidemic Patients: Time for a Change?Mayo Clinic Proceedings, 2010
- The LDL modification hypothesis of atherogenesis: an updateJournal of Lipid Research, 2009
- Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease RiskJACC, 2009
- Non–High-Density Lipoprotein and Very-Low-Density Lipoprotein Cholesterol and Their Risk Predictive Values in Coronary Heart DiseaseThe American Journal of Cardiology, 2006
- Apolipoproteins AI and B as therapeutic targetsJournal of Internal Medicine, 2006
- Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B ConcentrationsClinical Chemistry, 2005
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasmaAtherosclerosis, 1992